PB 01

Drug Profile

PB 01

Alternative Names: PB01

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Hudson Institute of Medical Research
  • Developer Paranta Biosciences
  • Class Carrier proteins; Glycoproteins; Recombinant proteins
  • Mechanism of Action Activin receptor antagonists; Cell differentiation modulators; Follicle stimulating hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis
  • Preclinical Cancer

Most Recent Events

  • 23 Nov 2016 Paranta completes a phase I trial in Healthy volunteers in Australia (ACTRN12616000496415)
  • 30 Sep 2015 Preclinical trials in Cancer in Australia (IV)
  • 22 Sep 2015 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Australia (Inhalation) (ACTRN12615000984594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top